Septerna, Inc.
About
31.05USD+1.26 +4.23%
Closed • Updated at 01:00 GMT+00:00Market Cap$1.40B
Volume219.2K
Beta0.66
RSI68.26
Gross Margin97.76%
Septerna, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 11 2026
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
May 5 2026
Septerna to Present at Bank of America Securities Health Care Conference
Apr 13 2026
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
Mar 9 2026
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Mar 1 2026
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
Recent Videos
Septerna Bold Moves:Dilution Risks & Strategic Partnerships #BiotechInvesting #InvestmentStrategies
Apr 07, 2026
노보 노디스크가 검증한 차세대 신약 기술 기업, Septerna(SEPN) #미국주식 #미국성장주
Jan 17, 2026
Septerna
Dec 17, 2025
My Key Insight from Septerna's Board Shake-Up 8-K
Oct 01, 2025
Community Chat
Ask AI
Try asking